The survival benefit of neoadjuvant chemotherapy for resectable colorectal liver metastases with high tumor burden score.
Colorectal cancer
Liver metastases
Neoadjuvant chemotherapy
Tumor burden score
Journal
International journal of clinical oncology
ISSN: 1437-7772
Titre abrégé: Int J Clin Oncol
Pays: Japan
ID NLM: 9616295
Informations de publication
Date de publication:
Jan 2021
Jan 2021
Historique:
received:
25
03
2020
accepted:
22
09
2020
pubmed:
20
10
2020
medline:
16
2
2021
entrez:
19
10
2020
Statut:
ppublish
Résumé
The indications for neoadjuvant chemotherapy (NAC) in resectable colorectal liver metastases (CRLMs) remain unclear. Tumor burden score (TBS) is a prognostic tool based on tumor size and number of tumors. However, its utility in the NAC setting for initially resectable CRLM has never been investigated. TBS is a distance from the origin on a Cartesian plane to the coordinates (x, y) = (tumor size in centimeter, number of tumors). TBS < 3 was defined as "TBS-low", whereas TBS ≥ 3 as "TBS-high". Between 2008 and 2018, 102 patients who underwent hepatectomy for resectable CRLM were retrospectively analyzed using the Kaplan-Meier method and Cox proportional hazards regression models. Among the TBS-low (n = 46) and TBS-high (n = 56) groups, baseline patient characteristics were mostly similar except for TBS-related parameters. NAC was more frequently administered in the TBS-high group (p = 0.038). The overall survival (OS) rates were similar between the two groups. Subgroup analysis showed that NAC was associated with non-significantly improved 5-year OS in the TBS-high group [76.1% with NAC and 54.9% without NAC (p = 0.093)]. In multivariate analysis, NAC was an independent prognostic factor for favorable OS only in the TBS-high group, while adjuvant chemotherapy (AC) was associated with improved OS only in the TBS-low group. In patients with resectable CRLM, the TBS-high population had a survival benefit from NAC, while the TBS-low population benefited from AC. TBS may serve as an indicator for patients who will benefit from NAC.
Sections du résumé
BACKGROUND
BACKGROUND
The indications for neoadjuvant chemotherapy (NAC) in resectable colorectal liver metastases (CRLMs) remain unclear. Tumor burden score (TBS) is a prognostic tool based on tumor size and number of tumors. However, its utility in the NAC setting for initially resectable CRLM has never been investigated.
METHODS
METHODS
TBS is a distance from the origin on a Cartesian plane to the coordinates (x, y) = (tumor size in centimeter, number of tumors). TBS < 3 was defined as "TBS-low", whereas TBS ≥ 3 as "TBS-high". Between 2008 and 2018, 102 patients who underwent hepatectomy for resectable CRLM were retrospectively analyzed using the Kaplan-Meier method and Cox proportional hazards regression models.
RESULTS
RESULTS
Among the TBS-low (n = 46) and TBS-high (n = 56) groups, baseline patient characteristics were mostly similar except for TBS-related parameters. NAC was more frequently administered in the TBS-high group (p = 0.038). The overall survival (OS) rates were similar between the two groups. Subgroup analysis showed that NAC was associated with non-significantly improved 5-year OS in the TBS-high group [76.1% with NAC and 54.9% without NAC (p = 0.093)]. In multivariate analysis, NAC was an independent prognostic factor for favorable OS only in the TBS-high group, while adjuvant chemotherapy (AC) was associated with improved OS only in the TBS-low group.
CONCLUSION
CONCLUSIONS
In patients with resectable CRLM, the TBS-high population had a survival benefit from NAC, while the TBS-low population benefited from AC. TBS may serve as an indicator for patients who will benefit from NAC.
Identifiants
pubmed: 33074351
doi: 10.1007/s10147-020-01793-9
pii: 10.1007/s10147-020-01793-9
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
126-134Références
House MG, Ito H, Gönen M et al (2010) Survival after hepatic resection for metastatic colorectal cancer: trends in outcomes for 1600 patients during two decades at a single institution. J Am Coll Surg 210:744–752
doi: 10.1016/j.jamcollsurg.2009.12.040
Kopetz S, Chang GJ, Overman MJ et al (2009) Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol 27:3677–3683
doi: 10.1200/JCO.2008.20.5278
Khatri VP, Petrelli NJ, Belghiti J (2005) Extending the frontiers of surgical therapy for hepatic colorectal metastases: is there a limit? J Clin Oncol 23:8490–8499
doi: 10.1200/JCO.2004.00.6155
Choti MA, Sitzmann JV, Tiburi MF et al (2002) Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann Surg 235:759–766
doi: 10.1097/00000658-200206000-00002
Khoo E, O’Neill S, Brown E et al (2016) Systematic review of systemic adjuvant, neoadjuvant and perioperative chemotherapy for resectable colorectal-liver metastases. HPB (Oxford) 18:485–493
doi: 10.1016/j.hpb.2016.03.001
Nigri G, Petrucciani N, Ferla F et al (2015) Neoadjuvant chemotherapy for resectable colorectal liver metastases: what is the evidence? results of a systematic review of comparative studies. Surgeon 13:83–90
doi: 10.1016/j.surge.2014.07.005
Nordlinger B, Sorbye H, Glimelius B et al (2008) Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet 371:1007–1016
doi: 10.1016/S0140-6736(08)60455-9
Nordlinger B, Sorbye H, Glimelius B et al (2013) Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial. Lancet Oncol 14:1208–1215
doi: 10.1016/S1470-2045(13)70447-9
Hokuto D, Nomi T, Yasuda S et al (2018) Risk factors for unresectable recurrence after up-front surgery for colorectal liver metastasis. World J Surg 42:884–891
doi: 10.1007/s00268-017-4195-0
Ayez N, van der Stok EP, Grünhagen DJ et al (2015) The use of neo-adjuvant chemotherapy in patients with resectable colorectal liver metastases: clinical risk score as possible discriminator. Eur J Surg Oncol 41:859–867
doi: 10.1016/j.ejso.2015.04.012
Tanaka K, Adam R, Shimada H et al (2003) Role of neoadjuvant chemotherapy in the treatment of multiple colorectal metastases to the liver. BJS 90:963–969
doi: 10.1002/bjs.4160
Beppu T, Sakamoto Y, Hasegawa K et al (2012) A nomogram predicting disease-free survival in patients with colorectal liver metastases treated with hepatic resection: multicenter data collection as a project study for hepatic surgery of the Japanese society of hepato-biliary-pancreatic surgery. J Hepatobiliary Pancreat Sci 19:72–84
doi: 10.1007/s00534-011-0460-z
Konopke R, Kersting S, Distler M et al (2009) Prognostic factors and evaluation of a clinical score for predicting survival after resection of colorectal liver metastases. Liver Int 29:89–102
doi: 10.1111/j.1478-3231.2008.01845.x
Rees M, Tekkis PP, Welsh FK et al (2008) Evaluation of long-term survival after hepatic resection for metastatic colorectal cancer: a multifactorial model of 929 patients. Ann Surg 247:125–135
doi: 10.1097/SLA.0b013e31815aa2c2
Nagashima I, Takada T, Adachi M et al (2006) Proposal of criteria to select candidates with colorectal liver metastases for hepatic resection: comparison of our scoring system to the positive number of risk factors. World J Gastroenterol 12:6305–6309
doi: 10.3748/wjg.v12.i39.6305
Iwatsuki S, Dvorchik I, Madariaga JR et al (1999) Hepatic resection for metastatic colorectal adenocarcinoma: a proposal of a prognostic scoring system. J Am Coll Surg 189:291–299
doi: 10.1016/S1072-7515(99)00089-7
Fong Y, Fortner J, Sun RL et al (1999) Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 230(3):309–318
doi: 10.1097/00000658-199909000-00004
Nordlinger B, Guiguet M, Vaillant JC et al (1996) Surgical resection of colorectal carcinoma metastases to the liver. A prognostic scoring system to improve case selection, based on 1568 patients. Association Francaise de Chirurgie Cancer 77:1254–1262
pubmed: 8608500
Zakaria S, Donohue JH, Que FG et al (2007) Hepatic resection for colorectal metastases: value for risk scoring systems? Ann Surg 246:183–191
doi: 10.1097/SLA.0b013e3180603039
Sasaki K, Morioka D, Conci S et al (2018) The tumor burden score: a new, “metro-ticket” prognostic tool for colorectal liver metastases based on tumor size and number of tumors. Ann Surg 267:132–141
doi: 10.1097/SLA.0000000000002064
Ayez N, van der Stok EP, de Wilt H et al (2015) Neo-adjuvant chemotherapy followed by surgery versus surgery alone in high-risk patients with resectable colorectal liver metastases: the CHARISMA randomized multicenter clinical trial. BMC Cancer 15:180
doi: 10.1186/s12885-015-1199-8
Portier G, Elias D, Bouche O et al (2006) Multicenter randomized trial of adjuvant fluorouracil and folinic acid compared with surgery alone after resection of colorectal liver metastases: FFCD ACHBTH AURC 9002 trial. J Clin Oncol 24:4976–4982
doi: 10.1200/JCO.2006.06.8353
Kato T, Uehara K, Maeda A et al (2015) Phase II multicenter study of adjuvant S-1 for colorectal liver metastasis: survival analysis of N-SOG 01 trial. Cancer Chemother Pharmacol 75:1281–1288
doi: 10.1007/s00280-015-2752-5
Mitry E, Fields AL, Bleiberg H et al (2008) Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer: a pooled analysis of two randomized trials. J Clin Oncol 26:4906–4911
doi: 10.1200/JCO.2008.17.3781
Mukai T, Uehara K, Goto H et al (2017) Phase II trial of neoadjuvant chemotherapy with S-1 and oxaliplatin plus bevacizumab for colorectal liver metastasis (N-SOG 05 trial). Jpn J Clin Oncol 47:597–603
doi: 10.1093/jjco/hyx048
Margonis GA, Sasaki K, Gholami S et al (2018) Genetic and morphological evaluation (GAME) score for patients with colorectal liver metastases. Br J Surg 105:1210–1220
doi: 10.1002/bjs.10838
Primrose J, Falk S, Finch-Jones M et al (2014) Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: the New EPOC randomised controlled trial. Lancet Oncol 15:601–611
doi: 10.1016/S1470-2045(14)70105-6